Recombinant Plasma Protein Therapeutics Market Analysis 2026

According to Cognitive Market Research, the global Recombinant Plasma Protein Therapeutics market size will be USD 15,241.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 5.80% from 2025 to 2033.

• North America held the major market share for more than 37% of the global revenue with a market size of USD 5639.47 million in 2025 and will grow at a compound annual growth rate (CAGR) of 3.6% from 2025 to 2033.
• Europe accounted for a market share of over 29% of the global revenue with a market size of USD 4420.12 million.
• APAC held a market share of around 24% of the global revenue with a market size of USD 3658.03 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2033.
• South America has a market share of more than 3.8% of the global revenue with a market size of USD 579.19 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.8% from 2025 to 2033.
• Middle East had a market share of around 4% of the global revenue and was estimated at a market size of USD 609.67 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2033.
• Africa had a market share of around 2.2% of the global revenue and was estimated at a market size of USD 335.32 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
• Recombinant Coagulation Factor VIII is the fastest growing segment of the Recombinant Plasma Protein Therapeutics industry

Introduction of the Recombinant Plasma Protein Therapeutics Market

Recombinant plasma protein therapeutics are biologically engineered proteins developed through recombinant DNA technology to mimic natural human plasma proteins. These proteins are used primarily in the treatment of blood-related disorders such as hemophilia (Factor VIII, IX), von Willebrand disease, and primary immunodeficiency disorders (immunoglobulins). Unlike traditional plasma-derived products, recombinant versions reduce the risk of contamination and blood-borne infections. They are also increasingly used in prophylactic treatments and surgical applications to manage bleeding disorders and improve patient outcomes.

In November 2023, the U.S. FDA approved Adzynma, the first recombinant ADAMTS13 enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP). The European Medicines Agency (EMA) granted approval in August 2024. ? https://www.takeda.com/newsroom/newsreleases/2023/takeda-adzynma-approved-by-fda-as-the-first-and-only-recombinant-adamts13-enzyme-replacement-therapy-for-the-treatment-of-congenital-thrombotic-thrombocytopenic-purpura”

Impact of Trump Tariffs on the Recombinant Plasma Protein Therapeutics Market

The imposition of tariffs on pharmaceutical imports from key partners such as China, Canada, and Mexico has led to increased production costs. For instance, a 25% tariff on goods from Canada and Mexico and a 10% tariff on Chinese imports have strained manufacturers who depend on these countries for raw materials and active pharmaceutical ingredients (APIs) . This has resulted in higher prices for end products and has exacerbated existing drug shortages in the U.S., particularly affecting generic drugmakers operating on thin profit margins.

In response to these tariffs, several pharmaceutical companies have announced significant investments in domestic manufacturing to mitigate supply chain disruptions. For example, AbbVie plans to invest over $10 billion in U.S. manufacturing over the next decade, including the construction of four new plants. Similarly, Amgen has announced a $900 million expansion of its biotech manufacturing facility in Ohio, increasing its total investment in the region to over $1.4 billion. While these moves aim to reduce dependency on foreign imports, the transition period may lead to temporary shortages and increased costs for patients.

Approximately 75% of U.S.-marketed medical devices are manufactured outside the country, exposing them significantly to tariff-induced price increases. Sources such as the New York Post, MedicalEconomics, and Medical Device Network have highlighted how this heavy reliance on international manufacturing has made the U.S. healthcare sector vulnerable to cost escalations following tariff implementations. Meanwhile, the U.S. medical equipment market, valued at $197.8 billion in 2023, is projected to grow steadily to $305.1 billion by 2033, reflecting a compound annual growth rate (CAGR) of 4.3%. This trend, reported by The Financial Express, MedicalEconomics, and Medical Buyer, suggests a resilient but increasingly cost-pressured market landscape.

Additionally, companies such as Thermo Fisher Scientific have experienced significant impacts from the tariff wars, with reported potential losses of up to $400 million in Chinese sales, amounting to approximately 8% of their total business. This data underscores the widespread economic repercussions of trade tensions, as emphasized by multiple industry sources.